Orforglipron versus oral semaglutide in type 2 diabetes, clinical implications of the ACHIEVE-3 trial

References

[1] American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2026 Diabetes Care 2026 49 S183 215 PMC12690185

[2] Ben Nasr M,Usuelli V,Dellepiane S.et al. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule Cell Metab 2024 36 1302 19.e12

[3] Zelniker TA,Wiviott SD,Raz I.et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus Circulation 2019 139 2022 31

[4] Gitto M,Catapano F,Francone M.et al. GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes Acta Diabetol 2026 63 179 91 PMC12957045

[5] McGuire DK,Marx N,Mulvagh SL.et al. ; SOUL Study Group. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes N Engl J Med 2025 392 2001 12

[6] Solis-Herrera C,Kane MP,Triplitt C. Current understanding of sodium N-(8-[2-Hydroxylbenzoyl] Amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience Clin Diabetes 2024 42 74 86 PMC10788673

[7] Frias JP,Hsia S,Eyde S.et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study Lancet 2023 402 472 83

[8] Pratt E,Ma X,Liu R.et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants Diabetes Obes Metab 2023 25 2634 41

[9] Rosenstock J,Yabe D,Cox D.et al. ; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Lancet 2026 407 1147 60

[10] Aroda VR,Aberle J,Bardtrum L.et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial Lancet 2023 402 693 704

[11] Rossi G,Bucciarelli L,Mananguite CL,Giovarelli M,Fiorina P. Muscle loss and GLP-1R agonists use Acta Diabetol 2026 63 333 42 PMC12957034

[12] Karakasis P,Patoulias D,Fragakis N,Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis Metabolism 2025 164 156113

[13] Aronne LJ,Horn DB,le Roux CW.et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Nat Med 2026 32 2679 87 PMC13375559